4//SEC Filing
SUPERNUS PHARMACEUTICALS INC 4
Accession 0001179110-12-007828
$SUPNCIK 0001356576operating
Filed
May 6, 8:00 PM ET
Accepted
May 7, 11:44 AM ET
Size
20.1 KB
Accession
0001179110-12-007828
Insider Transaction Report
Form 4
SHEFFERY MICHAEL B
Director
Transactions
- Conversion
Common Stock
2012-05-04+624,710→ 624,710 total(indirect: By OrbiMed Private Investments II (QP), LP) - Purchase
Common Stock
2012-05-04$5.00/sh+734,128$3,670,640→ 2,402,600 total(indirect: by OrbiMed Private Investments II LP) - Conversion
Common Stock
2012-05-04+1,668,472→ 1,668,472 total(indirect: By OrbiMed Private Investments II, LP) - Conversion
Common Stock
2012-05-04+206,816→ 206,816 total(indirect: By UBS Juniper Crossover Fund, L.L.C.) - Conversion
Series A Preferred Stock
2012-05-04−2,498,842→ 0 total(indirect: By OrbiMed Private Investments II (QP), LP)From: 2005-12-22→ Common Stock (624,710 underlying) - Purchase
Common Stock
2012-05-04$5.00/sh+274,873$1,374,365→ 899,583 total(indirect: By OrbiMed Private Investments II (QP), LP) - Purchase
Common Stock
2012-05-04$5.00/sh+90,999$454,995→ 297,815 total(indirect: By UBS Juniper Crossover Fund, L.L.C) - Conversion
Series A Preferred Stock
2012-05-04−6,673,891→ 0 total(indirect: By OrbiMed Private Investments II, LP)From: 2005-12-22→ Common Stock (1,668,472 underlying) - Conversion
Series A Preferred Stock
2012-05-04−827,627→ 0 total(indirect: By UBS Juniper Crossover Fund, L.L.C.)From: 2005-12-22→ Common Stock (206,816 underlying)
Footnotes (2)
- [F1]Each share of Series A Preferred Stock automatically converted into 0.25 shares of Common Stock (together the shares of Series A Preferred Stock and the shares of Common Stock, the "Shares") without payment of consideration upon the closing of the Issuer's initial public offering. Any fractional shares upon the conversion were paid out in cash. The shares of Series A Preferred Stock do not have an expiration date.
- [F2]Mr. Sheffery is a member of OrbiMed Advisors LLC, the managing member of OrbiMed Capital GP II LLC, which is the general partner of OrbiMed Private Investments II, LP and OrbiMed Private Investments II (QP), LP. Investment professionals employed by OrbiMed Advisors LLC manage UBS Juniper Crossover Fund, L.L.C.'s investment portfolio on behalf of UBS Juniper Management, L.L.C. Mr. Sheffery disclaims beneficial ownership of the Shares and this report shall not be deemed an admission that such reporting person is the beneficial owner of such Shares, except to the extent of his pecuniary interest, if any, in the Shares by virtue of his interest in OrbiMed Advisors LLC.
Documents
Issuer
SUPERNUS PHARMACEUTICALS INC
CIK 0001356576
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001356576
Filing Metadata
- Form type
- 4
- Filed
- May 6, 8:00 PM ET
- Accepted
- May 7, 11:44 AM ET
- Size
- 20.1 KB